Cart
sales@molnova.com
PI3K inhibitor X
CAS No. 956958-53-5
PI3K inhibitor X( XL-147 analog )
Catalog No. M16833 CAS No. 956958-53-5
PI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 85 | In Stock |
|
| 2MG | 30 | In Stock |
|
| 5MG | 48 | In Stock |
|
| 10MG | 76 | In Stock |
|
| 25MG | 135 | In Stock |
|
| 50MG | 212 | In Stock |
|
| 100MG | 365 | In Stock |
|
| 200MG | 475 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePI3K inhibitor X
-
NoteResearch use only, not for human use.
-
Brief DescriptionPI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor.
-
DescriptionPI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor of class I PI3Ks with IC50 of 39, 36, 23 and 383 nM for p110α, δ, γ and β respectively; Compound 147 in patent WO2012006552A1.
-
In Vitro——
-
In Vivo——
-
SynonymsXL-147 analog
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorDNA-PK|PI3Kα|PI3Kβ|PI3Kγ|PI3Kδ
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number956958-53-5
-
Formula Weight448.5208
-
Molecular FormulaC21H16N6O2S2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=S(C1=CC=C(C)C=C1)(NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4)=O
-
Chemical NameBenzenesulfonamide, N-[3-(2,1,3-benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Carlos L. Arteaga, et al. Combinations of kinase inhibitors for the treatment of cancer. WO 2012006552 A1.
molnova catalog
related products
-
AZD8186
AZD8186 is a potent, isoform-specific PI3Kβ inhibitor with IC50 of 4 nM, also inhibits PI3Kδ (IC50=12 nM) with selectivity over PI3Kα (IC50=35 nM) and PI3Kγ (IC50=675 nM).
-
RLY-2608
RLY-2608 is a selective mutant PI3Kα inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model.
-
Idelalisib (b)
Idelalisib is a selective inhibitor of p110δ(IC50 : 2.5 nM; in cell-free assays); shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
